Psilocybin Therapy for Clinicians With Symptoms of Depression After the Pandemic
Author Information
Author(s): Anthony L. Back, Timara K. Freeman-Young, Ladybird Morgan, Tanmeet Sethi, Kelsey K. Baker, Susanna Myers, Bonnie A. McGregor, Kalin Harvey, Marlene Tai, Austin Kollefrath, Brandon J. Thomas, Dennis Sorta, Kaelen Mendel, Benjamin Kelmendi, Ted A. Gooley
Primary Institution: University of Washington School of Medicine
Hypothesis
Does psilocybin therapy improve symptoms of depression, burnout, and posttraumatic stress disorder in clinicians who developed these symptoms from frontline clinical work during the COVID-19 pandemic?
Conclusion
Psilocybin therapy resulted in a significant, sustained reduction in symptoms of depression experienced by clinicians after frontline work during the COVID-19 pandemic.
Supporting Evidence
- Participants receiving psilocybin showed a mean change in MADRS scores of -21.33 compared to -9.33 in the niacin group.
- The study found a significant difference in depression symptom improvement between the psilocybin and niacin groups.
- Psilocybin therapy was associated with a sustained reduction in depression symptoms for up to 6 months.
- Participants reported a significant decrease in PTSD symptoms, although this was not statistically tested.
- 100% of participants had previously tried counseling and over 50% had tried an antidepressant.
Takeaway
This study shows that giving psilocybin to doctors and nurses who felt very sad after working during the pandemic helped them feel much better.
Methodology
This double-blind randomized clinical trial enrolled participants from February to December 2022, who were assigned to either the psilocybin or niacin arm, with outcomes measured using the Montgomery-Asberg Depression Rating Scale.
Potential Biases
Unknown biases may be present due to the small sample size and recruitment process.
Limitations
The small sample size may limit the generalizability of the findings, and functional unblinding was an issue as participants could distinguish between niacin and psilocybin after ingestion.
Participant Demographics
Participants included 30 clinicians (50% female, mean age 38 years) with no prepandemic mental health diagnoses but moderate to severe symptoms of depression.
Statistical Information
P-Value
<0.001
Confidence Interval
−17.67 to −6.33
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website